Herbert Smith Freehills (Brussels)

Peter Rowland

Herbert Smith Freehills (Brussels)
Counsel

Peter Rowland is a counsel in the competition, regulation and trade team at Herbert Smith Freehills, based in Brussels. He has over 15 years’ experience advising international clients on all aspects of EU and UK competition law, in particular merger control (M&A and joint ventures), cartel investigations, market investigations, horizontal and vertical agreements, and compliance programmes. He is dual-qualified in both Belgium (Advocaat, Brussels Bar) and England & Wales (Solicitor).

Distinctions

Linked authors

Herbert Smith Freehills (Melbourne)
Herbert Smith Freehills (London)
Herbert Smith Freehills (Johannesburg)
Herbert Smith Freehills (London)
Herbert Smith Freehills (London)

Articles

6823 Bulletin

Kyriakos Fountoukakos, Peter Rowland, Alexander Rickets The UK Competition Appeal Tribunal dismisses appeals against the Competition Authority’s findings of abuse of dominance relating to excessive pricing investigation concerning liothyronine tablets market (Advanz Pharma / Hg Capital / Cinven)

336

The UK Competition Appeal Tribunal has dismissed appeals against the CMA’s finding of abuse of dominance relating to excessive pricing of liothyronine tablets. The judgment provides further detail on the application of the excessive pricing test, and follows the Court of Appeal’s approach in (...)

Kyriakos Fountoukakos, Peter Rowland, Jose Munoz The EU Commission publishes the names of the companies that have declared that they meet the thresholds to qualify as gatekeepers under the Digital Markets Act (Alphabet / Amazon / Apple / ByteDance / Meta / Microsoft...)

403

On 4 July 2023, the European Commissioner for the Internal Market, Thierry Breton, revealed in a LinkedIn post the companies that have declared that they meet the thresholds to qualify as gatekeepers under the Digital Markets Act (DMA). The deadline for such notifications was yesterday, 3 July (...)

Kyriakos Fountoukakos, Daniel Vowden, Peter Rowland, Kristien Geeurickx The EU Commission publishes a package of measures aimed at simplifying its merger control procedures in order to reduce the workload and costs of mergers

62

On 20 April 2023 the European Commission published a package of measures aimed at simplifying its merger control procedures under the EU merger Regulation (EUMR). The new measures, which will take effect as of 1 September 2023, aim to streamline and make less burdensome the Commission’s (...)

Kyriakos Fountoukakos, Daniel Vowden, Peter Rowland, Laura Zsarnai, Violetta Meli The EU Commission publishes the ground-breaking Digital Markets Acts which aims at improving the contestability and fairness of digital markets

100

The EU’s groundbreaking Digital Markets Act (DMA) came into force on 1 November 2022 and applies from 2 May 2023. In this update we summarise key developments: the Implementing Regulation, institutional changes in DG COMP, workshops, and national proposals granting National Competition (...)

Kyriakos Fountoukakos, Daniel Vowden, Peter Rowland, Nika Nonveiller, Violetta Meli The EU Parliament publishes the Digital Markets Act in the Official Journal, creating a new regulatory regime for large tech platforms

175

The Digital Markets Act (DMA) is a ground-breaking piece of EU regulation, imposing rules on platforms acting as “gatekeepers” in the digital sector, and aiming to ensure fairness and contestability in digital markets. It will enter into force on 1 November 2022, setting the clock running for (...)

Kyriakos Fountoukakos, Peter Rowland, Jose Munoz The EU Commission issues a Statement of Objections against a pharmaceutical company over alleged abuse of dominance consisting of misuse of divisional patents and a disparagement campaign against its closest competitor (Teva)

758

On 10 October 2022, the European Commission (“EU Commission“) formally adopted a Statement of Objections (“SO“) against Teva over an alleged abuse of dominance concerning its blockbuster drug Copaxone, which is used in the treatment of multiple sclerosis. As we reported in March 2021, the EU (...)

Peter Rowland, Kristien Geeurickx, Kyriakos Fountoukakos The EU Commission reviews its guidelines on vertical restraints within the broader context of the review of the Vertical Block Exemption regulation

786

The European Commission (“Commission”) is currently reviewing its Guidelines on Vertical Restraints (“Vertical Guidelines”) within the broader context of the review of the Vertical Block Exemption Regulation (“VBER”) and consulted on its proposals last year. It has now launched a further (...)

Kyriakos Fountoukakos, Sebastien Moore, Peter Rowland, Kristien Geeurickx, Agathe Célarié The EU Court of Justice dismisses the appeals of several manufacturers of medicines and upholds the Commission’s decision regarding a pay-for-delay infringement (Lundbeck)

716

On 25 March 2021, the Court of Justice of the EU (“CJEU”) dismissed the appeals by Lundbeck and five producers of generic medicines against the General Court’s (GC) judgments that upheld the Commission’s decision and the fines it had imposed in its first pay-for-delay infringement decision in (...)

Marcel Nuys, Annika Gante, Peter Rowland, Kyriakos Fountoukakos, Florian Huerkamp The German Parliament passes the Digital Competition Act bringing significant changes to the competition law landscape

626

Today, the German parliament passed the “Digital Competition Act” which is the 10th amendment to the Act against Restraints of Competition (ARC). The amended law – which will very likely enter into force January 2021 – will bring about significant changes to the German competition law (...)

Kyriakos Fountoukakos, Peter Rowland, Marcel Nuys, Florian Huerkamp The German Competition Authority announces that it has initiated abuse proceedings against a social platform company for linkage with a virtual reality products brand (Oculus / Facebook)

230

The German FCO has not lost its appetite to take on major tech companies. Today, it has announced that it has initiated abuse proceedings against Facebook to examine the linkage between Oculus virtual reality products and Facebooks’ social network. The accusations against Facebook (...)

Mark Jephcott, Kyriakos Fountoukakos, Marcel Nuys, Peter Rowland, Tom Kemp, Anne Eckenroth The UK Competition Authority launches a market inquiry into the electric vehicle charging sector

165

The CMA has today (2 December 2020) launched a market study into the electric vehicle charging sector in the UK. The study will consider two broad themes: how to develop a competitive sector while also attracting private investment to help the sector grow; how to ensure people using electric (...)

Kyriakos Fountoukakos, André Pretorius, Marcel Nuys, Florian Huerkamp, Peter Rowland The EU Commission opens a formal investigation into an association of insurance companies to assess whether competitors were prevented from acessessing its data pool (Insurance Ireland)

18

On 14 May 2019, the EU Commission ("the Commission") announced that it has opened a formal antitrust investigation into Insurance Ireland, an association of insurance companies active in Ireland ("Investigation"). The association administers a database (Insurance Link), to which its member (...)

Kyriakos Fountoukakos, Marcel Nuys, Peter Rowland, Juliana Penz-Evren The German Competition Authority forces a social network company to change its data collection policy (Facebook)

113

On 7 February 2019, after almost three years of investigation, Germany’s Federal Cartel Office ("FCO") issued its long awaited decision on Facebook’s data collection practices. The FCO found that Facebook has a dominant position on the German market for social networks, and abused this (...)

Sebastien Moore, Kyriakos Fountoukakos, Mark Jephcott, Dafni Katrana, Peter Rowland The EU General Court hands down a judgment concerning an appeal brought by an undertaking and several generic companies against an EU Commission decision which found that the parties had breached Article 101 TFEU by agreeing to delay the market entry of a generic drug (Lundbeck)

116

On 8 September 2016 the General Court (GC) handed down its judgments in relation to the appeals brought by Lundbeck and a number of generic companies (Sun Pharma (Ranbaxy), Arrow, Generics UK, Merck and Xellia/Alpharma) against a European Commission (Commission) decision finding that the (...)

Statistics


6823
Total visits

324.9
Number of readings per contribution

21
Number of contributions

Author's ranking
453th
In number of contributions
1421th
In number of visits
5148th
In average number of visits
Send a message